Redefining antiplatelet regimens with the COATING trial data
The primary objective of the COATING trial was to evaluate whether surface modification on flow diverters (such as the P64 MW HPC and P48 HPC) could alter device properties to prevent platelet aggregation. Laurent Pierot explains that the COATING study directly compared a coated flow diverter paired with a single antiplatelet treatment (using prasugrel or ticagrelor) against a standard bare device paired with traditional dual antiplatelet therapy (DAPT).
The newly released one-year follow-up data from the COATING trial demonstrates exceptional non-inferiority and safety:
- Equivalent safety & occlusion: Overall safety and 12-month complete aneurysm occlusion rates (around 80%) were virtually identical in both groups, proving that single antiplatelet therapy does not increase thromboembolic complications.
- Accelerated healing: Interestingly, the COATING trial revealed a higher rate of complete occlusion at 6 months in the HPC group, suggesting that this specific coating promotes faster endothelialization and more rapid natural healing.
- No higher risk of in-stent stenosis: Despite the accelerated healing, the data showed that the coating did not trigger excessive endothelial hypertrophy or increase the risk of in-stent stenosis compared to bare stents.
Clinical implications and the future of the COATING trial
By focusing on evaluating the coating technology rather than a specific stent design, the COATING trial proves that HPC can be successfully applied across a broad spectrum of neurovascular devices and indications, from carotid stenting to distal flow diversion. Clinically, this allows operators to safely loosen strict DAPT protocols in borderline scenarios. It represents an immediate solution for patients presenting with high hemorrhagic risks, gastrointestinal bleeding histories, or known allergies to aspirin.
Looking ahead, the validated clinical confidence gained from the COATING trial under single antiplatelet regimens opens the door for future prospective research. The next logical frontier for the COATING trial framework will be evaluating efficacy in acute settings, such as ruptured aneurysms requiring flow diversion, where mitigating re-bleeding risks is paramount.
